Full Text View
Tabular View
No Study Results Posted
Related Studies
Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type
This study is ongoing, but not recruiting participants.
Study NCT00190411   Information provided by Assistance Publique - Hôpitaux de Paris
First Received: September 13, 2005   Last Updated: March 13, 2007   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Gene Map Locus 2q31
Additional conditions recognized in this trial
Ehlers-Danlos Syndrome
Syndrome
More general conditions related to this trial
Cardiovascular Diseases
Collagen Diseases
Congenital Abnormalities
Connective Tissue Diseases
Disease
Genetic Diseases, Inborn
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Pathologic Processes
Skin Abnormalities
Skin Diseases
Skin Diseases, Genetic
Vascular Diseases
Interventions listed in this trial
celiprolol
More general drug interventions related to this trial
Adrenergic Agents
Adrenergic Antagonists
Adrenergic beta-Antagonists
Anti-Arrhythmia Agents
Antihypertensive Agents
Autonomic Agents
Cardiovascular Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sympatholytics
Therapeutic Uses
Vasodilator Agents
Sponsors listed in this trial
Assistance Publique - Hôpitaux de Paris
Aventis Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services